Can an aspirin a day treat Parkinson’s disease (PD)? Not exactly, but the idea made headlines a few weeks ago, after scientists discovered that a key ingredient of aspirin might have potential to block the loss of brain cells in neurological diseases like PD and Alzheimer’s. As with every science headline, PDF asks, “what does it mean for people with PD?” In this case, we asked Michael Schwarzschild, M.D., Ph.D., of MassGeneral Institute of Neurodegenerative Disease, a well-known PD scientist who has also studied aspirin and ibuprofen in relation to PD. Here are his insights.
Last month, it was announced that two new drugs were approved by the US Food and Drug Administration, for treatment of Parkinson’s disease (PD). Both drugs, Rytary™ and Duopa™, are updates to carbidopa/levodopa. They offer, respectively, a newer formulation and delivery method to reduce off-times for those with PD. In this Q&A, PDF speaks with Myra Hirschhorn, one of our trained Research Advocates, to understand the community reaction to the approvals. As part of the Parkinson’s Advocates in Research program, Myra has been trained in the drug development process, and educates her community about research.
A few weeks ago, PDF staff and some of our volunteer Research Advocates attended a symposium that brings together scientists who are all focused on solving Parkinson’s disease: the 28th Annual Parkinson Study Group (PSG) Symposium in St. Louis, MO. The theme of this year’s symposium was disease modification, finding ways to not only ease symptoms, but also to change the progression of the disease. This starts with basic research to better understand what causes Parkinson’s disease, and ends with clinical trials testing drugs or compounds to ease symptoms or, hopefully, prevent Parkinson’s in the first place.
In this Q&A, Phil Myers shares his thoughts on volunteering as a PDF Research Advocate, and provides tips for individuals thinking of applying for a spot at our upcoming training for new advocates. Phil and his fellow 230 Research Advocates are part of PDF’s Parkinson’s Advocates in Research program. Q. Why did you apply to the PDF Learning Institute? A. A few years ago, my wife had passed away with a parkinsonism and I had recently been diagnosed with Parkinson’s disease. These experiences fueled my desire to be involved in medical research. But I didn’t have a medical background, so… Read More
Last month, the National Institute of Neurological Disorders and Stroke stopped one of the largest clinical trials for Parkinson’s disease to date. This trial was investigating whether a nutritional supplement, creatine, might have potential to treat Parkinson’s disease.
When opening the Sunday Review section of the New York Times this past weekend, I did a double-take as a topic of much discussion here at PDF was featured front and center – trumping commentary on the state of the economy, international relations and the latest political debate. “Do Clinical Trials Work?,” by Clifton Leaf serves as a primer on some of the key issues that prevail within the clinical research enterprise – the tension between scientific inquiry and patient priorities; the odds that study sponsors take when betting on the success of a potential therapy; and the disconnect between those who… Read More